Literature DB >> 19034048

Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.

Raquel P Dibi1, Claudio G Zettler, Suzana A Pessini, Alice V Ayub, Suzane B de Almeida, Gustavo P G da Silveira.   

Abstract

OBJECTIVE: To evaluate immunohistochemical, hysteroscopic, and histological findings in postmenopausal women taking tamoxifen for breast cancer.
METHODS: Forty postmenopausal women taking 20 mg/day tamoxifen for breast cancer underwent hysteroscopy and endometrial biopsy from January 2000 to December 2003. Medical records and paraffin blocks were analyzed retrospectively, and Ki-67, estrogen receptors (ERs), and progesterone receptors were measured using an immunohistochemical technique.
RESULTS: The mean +/- SD age of the women was 59 +/- 14 years at hysteroscopy (95% CI, 54.2-63.7) and 45.1 +/- 7 years at menopause (95% CI, 42.6-47.6). Mean +/- SD duration of tamoxifen therapy was 27.3 +/- 16.5 months (95% CI, 22.0-32.5). Hysteroscopies were performed because of abnormal sonographic findings in 60% of the women and postmenopausal bleeding in 40%. The most common hysteroscopic and histological findings were endometrial polyps (32.5%) and atrophic endometria (22.5%). Immunohistochemistry showed that 85% of the women were progesterone receptor positive, 75% were ER positive, and 50% were Ki-67 positive. Endometrial polyps and polyps associated with atrophic endometrium were ER positive (P = 0.019). Results that were ER negative were more frequent in atrophic endometria (P = 0.01). The longer the time since menopause, the lower the Ki-67 expression in the endometrium was (P = 0.03). Ki-67 expression was greater in the endometrium of younger postmenopausal women (P = 0.01).
CONCLUSIONS: The expression of steroid receptors in the endometrium was high in our series. All cases of endometrial polyps were ER positive. Estrogen receptors may play a major role in the development of endometrial polyps in postmenopausal women taking tamoxifen. Although most histological findings were benign, 22.5% were atrophic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19034048     DOI: 10.1097/gme.0b013e31818af10a

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  4 in total

1.  Unusual case of a sigmoid mass.

Authors:  Caris Grimes; Olatunde Lalude
Journal:  J Gastrointest Cancer       Date:  2010-03

2.  Differences in estrogen and progesterone receptor expression in endometrial polyps and atrophic endometrium of postmenopausal women with and without exposure to tamoxifen.

Authors:  Rogerio Barros Ferreira Leão; Liliana Andrade; Jose Vassalo; Armando Antunes; Aarão Pinto-Neto; Lucia Costa-Paiva
Journal:  Mol Clin Oncol       Date:  2013-09-12

3.  Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women.

Authors:  Carlo Saccardi; Amerigo Vitagliano; Matteo Marchetti; Alice Lo Turco; Sofia Tosatto; Michela Palumbo; Luciana Serena De Lorenzo; Salvatore Giovanni Vitale; Marco Scioscia; Marco Noventa
Journal:  Diagnostics (Basel)       Date:  2020-04-27

4.  Whole-lesion apparent diffusion coefficient (ADC) histogram as a quantitative biomarker to preoperatively differentiate stage IA endometrial carcinoma from benign endometrial lesions.

Authors:  Jieying Zhang; Xiaoduo Yu; Xiaomiao Zhang; Shuang Chen; Yan Song; Lizhi Xie; Yan Chen; Han Ouyang
Journal:  BMC Med Imaging       Date:  2022-08-08       Impact factor: 2.795

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.